Nuvalent, Inc. Class A (NUVL)
NASDAQ:NUVL
Want to see NUVL full AI Analyst Report?
Top Page
Nuvalent
(NASDAQ:NUVL)
Select Model
Select Model
Rating:69Neutral
Price Target:
$135.00
▲(25.45% Upside)
Action:Reiterated
Date:06/19/26
The score is driven primarily by weak financial performance (no revenue, widening losses, and significant cash burn) offset by a strong balance sheet and highly supportive corporate events (announced GSK cash acquisition and regulatory milestone). Technicals are strong with clear upward trend, while valuation support is limited due to negative earnings and no dividend.
Positive Factors
Balance sheet strength
Zero reported debt and roughly $1.17B of equity give the company durable financial flexibility to fund clinical programs and negotiations. Low leverage reduces refinancing risk, supports R&D spending cadence, and provides a buffer versus short-term funding shocks over the next several months.
Negative Factors
Pre-revenue with widening losses
Being pre-revenue while incurring rapidly expanding R&D and operating losses creates a persistent profitability gap. Without product sales, the company depends on milestone outcomes or transaction execution to justify capital deployment and restore earnings potential over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Zero reported debt and roughly $1.17B of equity give the company durable financial flexibility to fund clinical programs and negotiations. Low leverage reduces refinancing risk, supports R&D spending cadence, and provides a buffer versus short-term funding shocks over the next several months.
Read all positive factors
Nuvalent (NUVL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.76B
Dividend YieldN/A
Average Volume (3M)3.48M
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue GrowthN/A
EPS Growth-37.66%
CountryUS
Employees162
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.06
Shares Outstanding73,562,660
10 Day Avg. Volume8,825,244
30 Day Avg. Volume3,477,087
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)5.86
Price to Sales (P/S)0.00
P/FCF Ratio-26.57
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-26.66
Forecast
1Y Price Target
$125.18Price Target Upside16.33% Upside
Rating ConsensusHold
Number of Analyst Covering18
EPS Forecast (FY)-5.65
Revenue Forecast (FY)$11.21M
Nuvalent Business Overview & Revenue Model
Company Description
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selecti...
How the Company Makes Money
Nuvalent is a clinical-stage company and, as of publicly available information up to my knowledge cutoff (2025-09), does not have approved commercial products. As a result, it does not generate recurring product sales revenue; its operations are p...
Nuvalent Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -334.38M | -10.48M | 20.38M | -126.22M | -81.85M | -46.12M |
| Net Income | -450.07M | -425.38M | -260.76M | -126.22M | -81.85M | -46.34M |
Balance Sheet | ||||||
| Total Assets | 1.33B | 1.41B | 1.14B | 732.38M | 482.46M | 293.82M |
| Cash, Cash Equivalents and Short-Term Investments | 1.29B | 1.37B | 1.12B | 719.90M | 472.16M | 288.11M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 156.78M | 164.37M | 71.96M | 31.82M | 19.48M | 8.79M |
| Stockholders Equity | 1.17B | 1.25B | 1.07B | 700.56M | 462.98M | 285.04M |
Cash Flow | ||||||
| Free Cash Flow | -312.79M | -275.21M | -185.06M | -99.74M | -64.97M | -40.00M |
| Operating Cash Flow | -312.79M | -275.21M | -185.06M | -99.74M | -64.97M | -40.00M |
| Investing Cash Flow | -168.91M | -124.08M | -573.51M | -143.53M | -10.66M | -220.03M |
| Financing Cash Flow | 520.59M | 515.34M | 568.88M | 336.85M | 248.92M | 318.22M |
Nuvalent Technical Analysis
Positive
107.61
Price Trends
107.57
Positive
104.52
Positive
100.77
Positive
Market Momentum
5.78
Negative
66.85
Neutral
70.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUVL, the sentiment is Positive. The current price of 107.61 is below the 20-day moving average (MA) of 113.14, above the 50-day MA of 107.57, and above the 200-day MA of 100.77, indicating a bullish trend. The MACD of 5.78 indicates Negative momentum. The RSI at 66.85 is Neutral, neither overbought nor oversold. The STOCH value of 70.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NUVL.
Nuvalent Risk Analysis
Nuvalent disclosed 90 risk factors in its most recent earnings report. Nuvalent reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nuvalent Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $8.55B | 17.56 | 87.36% | ― | 81.26% | 1079.73% | |
69 Neutral | $9.76B | -20.38 | -42.78% | ― | ― | -37.66% | |
60 Neutral | $12.44B | -64.79 | -260.01% | ― | 63.88% | 35.18% | |
52 Neutral | $10.23B | -12.03 | 139.66% | ― | 450.60% | -28.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $225.62M | -4.94 | -29.67% | ― | ― | ― |
* Healthcare Sector Average
NUVL
Nuvalent
123.52
47.22
61.89%
CYTK
Cytokinetics
82.19
49.15
148.76%
TGTX
TG Therapeutics
55.83
19.84
55.13%
AXSM
Axsome Therapeutics
241.67
137.28
131.51%
RNA
Atrium Therapeutics, Inc.
13.19
-1.56
-10.58%
Nuvalent Corporate Events
Executive/Board ChangesShareholder Meetings
Nuvalent Shareholders Endorse Board, Pay, and Auditor
Positive
Jun 18, 2026
At its 2026 Annual Meeting of Stockholders held on June 16, 2026, Nuvalent reported that 71,190,894 Class A shares were represented, accounting for approximately 96.8% of outstanding Class A stock as of the April 20, 2026 record date, underscoring...
Business Operations and StrategyM&A Transactions
Nuvalent to Be Acquired by GSK in Cash Deal
Positive
Jun 9, 2026
On 9 June 2026, Nuvalent entered into a merger agreement under which GlaxoSmithKline will launch a tender offer to acquire all Nuvalent Class A and B shares for $124 in cash per share, valuing the oncology specialist at about $10.6 billion. The bo...
Product-Related AnnouncementsRegulatory Filings and Compliance
Nuvalent Files FDA Application for Lung Cancer Therapy
Positive
Apr 7, 2026
On April 7, 2026, Nuvalent, Inc. reported that it had submitted a New Drug Application to the U.S. Food and Drug Administration for neladalkib, a treatment candidate for patients with tyrosine kinase inhibitor pre-treated advanced ALK-positive non...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.